ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Glioblastoma Advanced Brain Cancer Treatments & Care: Sep 2025 Fundraiser Update

Asta Pratapaviciene's drive to help fund advanced glioblastoma treatment for her partner Raimondas continues to need community support, having reached less than 7% of the target as of September 2025.

-- Asta Pratapaviciene announced that as of September 2025, the fundraiser 'You're My Only Hope' has raised £6,850 of the £100,000 needed for her partner, Raimondas, who was diagnosed earlier this year with glioblastoma. The campaign aims to cover the cost of specialised private treatment that is not available under standard National Health Service (NHS) care.

More details are available at https://gofund.me/c11576b0

Current data from Cancer Research UK shows glioblastoma is the most common malignant and aggressive form of brain cancer in adults. Around 3,200 to 4500 people are diagnosed each year in the UK. Despite surgery, chemotherapy, and radiotherapy being standard treatments, survival rates remain low. The median overall survival is typically 12 to 15 months, with fewer than 5% of patients living beyond five years.

Because glioblastoma is resistant to many conventional therapies, researchers are exploring new strategies such as immunotherapy, tumour‑treating fields, and precision‑based genetic approaches. These treatments remain largely unavailable on the NHS because of high secondary care costs (potentially exceeding £9,000 per month), limited long‑term data, and ongoing clinical trials.

For cancer patients like Raimondas, private care or medical tourism are among the few ways to access new therapies. Even with these options, scholars at Cambridge University note that glioblastomas are hard to remove, inaccessible to standard chemotherapy drugs, and many patients are 'often ineligible for surgery due to co-morbidities or proximity of the tumour to vital structures.'

Asta described the impact of the diagnosis on their lives:

"We met eight years ago, both emerging from difficult divorces, and finally found happiness and peace in each other. We were planning our future together when everything changed overnight with this heartbreaking diagnosis—and the costs are not something we can manage on our own. That's why we're asking for help."

Since launching, the fundraiser has drawn support from more than 160 donors. Contributions are protected under the GoFundMe Giving Guarantee, which provides donor protection worldwide.

Every donation will go directly toward treatment expenses in hopes of giving Raimondas more time and access to options beyond standard care. The GoFundMe campaign aims to raise awareness about the challenges faced by patients, caregivers, and families in finding effective treatments for glioblastoma.

For more information, or to support the campaign, visit https://gofund.me/c11576b0

Contact Info:
Name: Asta Pratapaviciene
Email: Send Email
Organization: Asta Pratapaviciene
Address: 28 Gilbert Drive Langdon Hills, Basildon, Essex SS16 6SP, United Kingdom
Website: https://gofund.me/c11576b0

Source: PressCable

Release ID: 89169503

Should you detect any errors, issues, or discrepancies with the content contained within this press release, or if you need assistance with a press release takedown, we kindly request that you inform us immediately by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond and take necessary steps within the next 8 hours to resolve any identified issues or guide you through the removal process. We value the trust placed in us by our readers and remain dedicated to providing accurate and reliable information.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.